Cited by 246Inhalation and Respiratory Drug DeliveryNanoparticle-Based Drug DeliveryAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 124 of the 127 references it cites were found in a registry or an index.

Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases

Open access

Andrade, Fernanda, Rafael, Diana, Videira, Mafalda, Ferreira, Domingos, Sosnik, Alejandro, Sarmento, Bruno·2013·Advanced Drug Delivery Reviews

DOI 10.1016/j.addr.2013.07.020PMC PMC7103277

Open this paper in CoChat — free account Open PDF

Abstract

Used since ancient times especially for the local treatment of pulmonary diseases, lungs and airways are a versatile target route for the administration of both local and systemic drugs. Despite the existence of different platforms and devices for the pulmonary administration of drugs, only a few formulations are marketed, partly due to physiological and technological limitations. Respiratory infections represent a significant burden to health systems worldwide mainly due to intrahospital infections that more easily affect immune-compromised patients. Moreover, tuberculosis (TB) is an endemic infectious disease in many developing nations and it has resurged in the developed world associated with the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic. Currently, medicine faces the specter of antibiotic resistance. Besides the development of new anti-infectious drugs, the development of innovative and more efficient delivery systems for drugs that went off patent appears as a promising strategy pursued by the pharmaceutical industry to improve the therapeutic outcomes and to prolong the utilities of their intellectual property portfolio. In this context, nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.addr.2013.07.020

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Cyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 2,057
International Conference on Harmonisation
Guy, R. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,487
Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.
Labiris, N., & Dolovich, M. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01892.x · Cited by 1,212
Global Tuberculosis Control 2011, WHO Report 2011
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 1,009
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904
Formulation strategy and use of excipients in pulmonary drug delivery
Pilcer, G., & Amighi, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.017 · Cited by 816
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Influence of particle size on regional lung deposition – What evidence is there?
Carvalho, T. C., Peters, J. I., & Williams III, R. O. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.040 · Cited by 614
An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
LIMPER, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Global Tuberculosis Control: WHO Report 2011
Williams, C. (2012) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2012.00928.x · Cited by 588
Targeting to macrophages: role of physicochemical properties of particulate carriers–liposomes and microspheres – on the phagocytosis by macrophages
Ahsan, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00549-1 · Cited by 570
Dry Powder Inhaler Formulation
Telko, M. J., & Hickey, A. J. (2005) · Respiratory Care · doi:10.4187/respcare.05501209 · Cited by 515
Aerosol drug delivery: developments in device design and clinical use
DOLOVICH, M. B., & Dhand, R. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60926-9 · Cited by 506
Nanomedicine in pulmonary delivery
Mansour, H. M., Haemosu, & Wu, X. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s4937 · Cited by 497
Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications
Labiris, N. R., & DOLOVICH, M. B. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01893.x · Cited by 452
Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications
Pinto‐Alphandary, H., Andremont, A., & Couvreur, P. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(99)00121-1 · Cited by 443
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 389
Emerging nanopharmaceuticals
Bawarski, W. E., Chidlowsky, E., Bharali, D. J., & Mousa, S. A. (2008) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.06.002 · Cited by 342
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314
Nanoparticle formulations in pulmonary drug delivery
Bailey, M. M., & Berkland, C. J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20140 · Cited by 302
Biodegradable polymeric nanocarriers for pulmonary drug delivery
Rytting, E., Nguyen, J., Wang, X., & Kissel, T. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.6.629 · Cited by 266
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Sosnik, A., Carcaboso, A. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.023 · Cited by 264
Self-citation
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages
Vyas, S. P., Kannan, M., Jain, S., Mishra, V. K., & Singh, P. (2003) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.08.017 · Cited by 262
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis
Sharma, A., Sharma, S., & Khuller, G. K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh411 · Cited by 251
Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
Vandamme (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s1045 · Cited by 238
Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro
Grenha, A., Grainger, C. I., Dailey, L. A., Seijo, B., Martin, G. P., Remuñán‐López, C., & Forbes, B. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.02.008 · Cited by 222
Pneumonia in the intensive care unit
Rello, J., & Dı́az, E. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000089928.84326.d2 · Cited by 202
Inhalation therapy: an historical review
Sanders, M. (2007) · Primary Care Respiratory Journal · doi:10.3132/pcrj.2007.00017 · Cited by 199
Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells
Fattal, E., Mura, S., Nicolas, J., Hillaireau, H., Gueutin, Droumaguet, B. L., Zanna, S., & Tsapis, N. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s24552 · Cited by 192
Antitubercular inhaled therapy: opportunities, progress and challenges
Pandey, R., & Khuller, G. K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki027 · Cited by 188
One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis
Ohashi, K., Kabasawa, T., Ozeki, T., & Okada, H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.027 · Cited by 178
The antimicrobial efficacy of sustained release silver–carbene complex-loaded l-tyrosine polyphosphate nanoparticles: Characterization, in vitro and in vivo studies
Hindi, K. M., Ditto, A. J., Panzner, M. J., Medvetz, D. A., Han, D., Hovis, C. E., Hilliard, J. K., Taylor, J. B., Yun, Y., Cannon, C. L., et al. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.044 · Cited by 171
Respiratory viral infections in patients with chronic, obstructive pulmonary disease
Beckham, J. D., Cadena, A., Lin, J., Piedra, P. A., Glezen, W. P., Greenberg, S. B., & Atmar, R. L. (2004) · Journal of Infection · doi:10.1016/j.jinf.2004.07.011 · Cited by 168
Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections
Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.011 · Cited by 164
Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection
Omri, A., Suntres, Z. E., & Shek, P. N. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01346-1 · Cited by 160
Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in An Infectious Disease Model
Suarez, S., O’Hara, P. J., Kazantseva, M., Newcomer, C. E., Hopfer, R. L., McMurray, D. N., & Hickey, A. J. (2001) · Pharmaceutical Research · doi:10.1023/a:1013094112861 · Cited by 159
Airways delivery of rifampicin microparticles for the treatment of tuberculosis
Suarez, S. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.431 · Cited by 156
Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection
Wong, J. P., Yang, H., Blasetti, K. L., Schnell, G., Conley, J., & Schofield, L. N. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00358-4 · Cited by 153
FDA's Approach to Regulation of Products of Nanotechnology
Hamburg, M. A. (2012) · Science · doi:10.1126/science.1205441 · Cited by 152
International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.
(2010) · PubMed · Cited by 150
Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains
Alipour, M., Halwani, M., Omri, A., & Suntres, Z. E. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.11.035 · Cited by 148
Inhaled Drug Delivery for Tuberculosis Therapy
Muttil, P., Wang, C., & Hickey, A. J. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9957-4 · Cited by 148
Guidance for Industry Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology
(2011) · Biotechnology Law Report · doi:10.1089/blr.2011.9814 · Cited by 146
Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig Model
Garcia‐Contreras, L., Fiegel, J., Telko, M. J., Elbert, K. J., Hawi, A. A., Thomas, M., VerBerkmoes, J. L., Germishuizen, W. A., Fourie, P. B., Hickey, A. J., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01164-06 · Cited by 139
Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study
Aitken, M. L. (1992) · JAMA · doi:10.1001/jama.267.14.1947 · Cited by 139
Nanodelivery in airway diseases: Challenges and therapeutic applications
Roy, I., & Vij, N. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.07.001 · Cited by 137
HYPERGLYCAEMIA AND DIABETES AFTER BURNS.
Piggott, H. (1965) · PubMed · Cited by 137
Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis with Pseudomonas aeruginosa
Geller, D. E., Flume, P. A., Staab, D., Fischer, R., Loutit, J., & Conrad, D. J. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201008-1293oc · Cited by 132
Liposomes for drug delivery to the lungs by nebulization
Zaru, M., Mourtas, S., Klepetsanis, P. G., Fadda, A. M., & Antimisiaris, S. G. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.04.005 · Cited by 131
Characterization of a surface modified dry powder inhalation carrier prepared by “particle smoothing”
Young, P. M., Cocconi, D., Colombo, P., Bettini, R., Price, R., Steele, D. F., & Tobyn, M. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/002235702760345400 · Cited by 130
Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect
Videira, M., Almeida, A. J., & Fabra, À. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.12.007 · Cited by 128
Self-citation
Chitosan-coated liposomes for delivery to lungs by nebulisation
Zaru, M., Manca, M. L., Fadda, A. M., & Antimisiaris, S. G. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.01.010 · Cited by 120
History of Aerosol Therapy: Liquid Nebulization to MDIs to DPIs
ANDERSON, P. J. (2005) · Respiratory Care · doi:10.4187/respcare.05501139 · Cited by 120
The Failure of Exubera: Are We Beating a Dead Horse?
Heinemann, L. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200325 · Cited by 119
Dry Powder Inhaler Device Influence on Carrier Particle Performance
Donovan, M. J., Kim, S. H., Raman, V., & Smyth, H. D. C. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22824 · Cited by 118
Liposomes as Drug Delivery Systems for The Treatment of TB
Pinheiro, M., Lúcio, M., Lima, J. L. F. C., & Reis, S. (2011) · Nanomedicine · doi:10.2217/nnm.11.122 · Cited by 114
Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery
Sweeney, L. G., Wang, Z., Löebenberg, R., Wong, J. P., Lange, C. F., & Finlay, W. H. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.09.010 · Cited by 112
High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers
Yang, W. P., Tam, J. M., Miller, D. A., Zhou, J., McConville, J. T., Johnston, K. P., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.05.003 · Cited by 112
Prevention and Treatment ofStaphylococcus aureusPneumonia with a β-Cyclodextrin Derivative
Ragle, B. E., Karginov, V. A., & Wardenburg, J. B. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00973-09 · Cited by 111
Physicochemical Characterization and Stability of Rifampicin Liposome Dry Powder Formulations for Inhalation
Changsan, N., Chan, H., Separovic, F., & Srichana, T. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21441 · Cited by 108
Recombinant Human DNase Inhalation in Normal Subjects and Patients With Cystic Fibrosis
Aitken, M. L. (1992) · JAMA · doi:10.1001/jama.1992.03480140073036 · Cited by 107
New respiratory viral infections
Jartti, T. T., Jartti, L., Ruuskanen, O., & Söderlund‐Venermo, M. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328351f8d4 · Cited by 105
Formulation of rifampicin–cyclodextrin complexes for lung nebulization
Tewes, F., Brillault, J., Couet, W. R., & Olivier, J. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.007 · Cited by 103
Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis
Hwang, S., Kim, D. D., Chung, S., & Shim, C. K. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.009 · Cited by 103
Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages
Vyas, S. P., QURAISHI, S., Gupta, S., & Jaganathan, K. S. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.02.003 · Cited by 100
Biomedical Detection via Macro- and Nano-Sensors Fabricated with Metallic and Semiconducting Oxides
Hahm, J. (2012) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2013.1468 · Cited by 98
Steroid Aerosols in Asthma: An Assessment of Betamethasone Valerate and a 12-month Study of Patients on Maintenance Treatment
McAllen, M. K., Kochanowski, S. J., & Shaw, K. M. (1974) · BMJ · doi:10.1136/bmj.1.5900.171 · Cited by 94
Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: ICH M3 and M3(R2)
Sjöberg, P. J. R., & Jones, D. R. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-5950-7_14 · Cited by 92
Viral respiratory tract infections and asthma: The course ahead
Rosenthal, L. A., Avila, P. C., Heymann, P. W., Martin, R. J., Miller, E. K., Papadopoulos, N. G., Peebles, R. S., & Gern, J. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.002 · Cited by 91
Hydrolyzed Galactomannan-Modified Nanoparticles and Flower-Like Polymeric Micelles for the Active Targeting of Rifampicin to Macrophages
Moretton, M. A., Chiappetta, D. A., Andrade, F., das Neves, J., Ferreira, D., Sarmento, B. F. C. C., & Sosnik, A. (2013) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2013.1600 · Cited by 91
Self-citation
Single dose and multiple dose studies of itraconazole nanoparticles
Vaughn, J. M., McConville, J. T., Burgess, D., Peters, J. I., Johnston, K. P., Talbert, R. L., & Williams, R. O. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.01.006 · Cited by 85
Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice
Agarwal, A., Kandpal, H., Gupta, H. P., Singh, N. B., & Gupta, C. M. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.588 · Cited by 81
Enhanced killing of methicillin-resistantStaphylococcus aureus in human macrophages by liposome-entrapped vancomycin and teicoplanin
Onyeji, C. O., Nightingale, C. H., & Marangos, M. N. (1994) · Infection · doi:10.1007/bf01715542 · Cited by 79
Preparation and use of Liposomes in the Treatment of Microbial Infections
Swenson, C. E., Popescu, M. C., Ginsberg, R. S., & Juliano, R. L. (1988) · CRC Critical Reviews in Microbiology · doi:10.3109/10408418809104463 · Cited by 78
Incorporation of Antibiotics in Liposomes Designed for Tuberculosis Therapy by Inhalation
Justo, O. R., & Moraes, Â. M. (2003) · Drug Delivery · doi:10.1080/713840401 · Cited by 77
Nanocarriers for Pulmonary Administration of Peptides and Therapeutic Proteins
Andrade, F., Videira, M., Ferreira, D., & Sarmento, B. F. C. C. (2010) · Nanomedicine · doi:10.2217/nnm.10.143 · Cited by 76
Self-citation
Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages:in vitroandin vivoevaluation
Zaru, M., Sinico, C., Logu, A. D., Caddeo, C., Lai, F., Manca, M. L., & Fadda, A. M. (2009) · Journal of Liposome Research · doi:10.1080/08982100802610835 · Cited by 73
Targeted High Lung Concentrations of Itraconazole Using Nebulized Dispersions in a Murine Model
McConville, J. T., Overhoff, K. A., Sinswat, P., Vaughn, J. M., Frei, B. L., Burgess, D. S., Talbert, R. L., Peters, J. I., Johnston, K. P., & Williams, R. O. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9904-6 · Cited by 65
A History of Nebulization
Dessanges, J. F. (2001) · Journal of Aerosol Medicine · doi:10.1089/08942680152007918 · Cited by 61
Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats
Marier, J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg317 · Cited by 61
Rationale for and Efficacy of Prolonged-Interval Treatment Using Liposome-Encapsulated Amikacin in Experimental Mycobacterium avium Infection
Leitzke, S., Bucke, W., Börner, K., Müller, R. H., Hahn, H. H., & Ehlers, S. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.459 · Cited by 59
Pure Insulin Nanoparticle Agglomerates for Pulmonary Delivery
Bailey, M. M., Gorman, E. M., Munson, E. J., & Berkland, C. J. (2008) · Langmuir · doi:10.1021/la802405p · Cited by 56
Pulmonary Immunization Using Antigen 85-B Polymeric Microparticles to Boost Tuberculosis Immunity
Lu, D., Garcia‐Contreras, L., Muttil, P., Padilla, D., Xu, D., Liu, J., Braunstein, M., McMurray, D. N., & Hickey, A. J. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9193-1 · Cited by 56
Antibacterial activity of liposome-entrapped streptomycin in mice infected with mycobacterium tuberculosis.
Vladimirsky, M. A., & Ga, L. (1982) · PubMed · Cited by 56
Interactions of pluronic block copolymers on P‐gp efflux activity: Experience with HIV‐1 protease inhibitors
Shaik, N., Pan, G., & Elmquist, W. F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21372 · Cited by 55
Superior Chemotherapeutic Efficacy of Amphotericin B in Tuftsin-bearing Liposomes against Leishmania Donovani Infection in Hamsters
Agrawal, A. K., Agrawal, A., Pal, A. K., Guru, P. Y., & Gupta, C. M. (2002) · Journal of drug targeting · doi:10.1080/10611860290007513 · Cited by 54
Development of Respirable Nanomicelle Carriers for Delivery of Amphotericin B by Jet Nebulization
Gilani, K., Moazeni, E., Ramezanli, T., Amini, M., Fazeli, M. R., & Jamalifar, H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22274 · Cited by 53
Liposome-based drug delivery to alveolar macrophages
Vyas, S. P., & Khatri, K. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.2.95 · Cited by 52
Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment
Justo, O. R., & Moraes, Â. M. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357055092 · Cited by 50
Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes
Gangadharam, P. R., Ashtekar, D. R., Flasher, D., & Düzgüneş, N. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.725 · Cited by 49
Future of Nanomedicine: Obstacles and Remedies
Bosetti, R., & Vereeck, L. (2011) · Nanomedicine · doi:10.2217/nnm.11.55 · Cited by 48
In Vivo Efficacy of Aerosolized Nanostructured ItraconazoleFormulations for Prevention of Invasive Pulmonary Aspergillosis
Hoeben, B. J., Burgess, D. S., McConville, J. T., Najvar, L. K., Talbert, R. L., Peters, J. I., Wiederhold, N. P., Frei, B. L., Graybill, J. R., Bocanegra, R. A., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1552-1554.2006 · Cited by 46
Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis
Alvarez, C. A., Wiederhold, N. P., McConville, J. T., Peters, J. I., Najvar, L. K., Graybill, J. R., Coalson, J. J., Talbert, R. L., Burgess, D. S., Bocanegra, R., et al. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.01.014 · Cited by 43
Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study
Huland, E., Burger, A., Fleischer, J., Fornara, P., Hatzmann, E., Heidenreich, A., Heinzer, H., Heynemann, H., Hoffmann, L., Hofmann, R., et al. (2003) · Folia Biologica · doi:10.14712/fb2003049050183 · Cited by 42
Tuftsin‐bearing liposomes as drug vehicles in the treatment of experimental aspergillosis
Owais, M., Ahmed, I., Krishnakumar, B., Jaina, R. K., Bachhawat, B. K., & Gupta, C. M. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81760-w · Cited by 37
The activity of low-clearance liposomal amikacin in experimental murine tuberculosis
Dhillon, J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.869 · Cited by 37
Rehydrated Lyophilized Rifampicin-Loaded mPEG–DSPE Formulations for Nebulization
Abdulla, J. M. A., Tan, Y. T.-F., & Darwis, Y. (2010) · AAPS PharmSciTech · doi:10.1208/s12249-010-9428-6 · Cited by 36
Tuftsin-Bearing Liposomes as Antibiotic Carriers in Treatment of Macrophage Infections
Gupta, C. M., & Haq, W. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)91016-1 · Cited by 35
Therapeutic Efficacy of Liposome-encapsulated Kanamycin against Mycobacterium intracellulare Infection Induced in Mice
Tomioka, H., Saito, H., Sato, K., & Yoneyama, T. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.3_pt_1.575 · Cited by 35
Delivery of liposomes in dry powder form: aerodynamic dispersion properties
Desai, T. R., Hancock, R. E. W., & Finlay, W. H. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.09.008 · Cited by 35
Aerosol vaccines for tuberculosis: A fine line between protection and pathology
Hokey, D. A., & Misra, A. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.09.007 · Cited by 34
Spray‐dried carrier‐free dry powder tobramycin formulations with improved dispersion properties
Pilcer, G., Vanderbist, F., & Amighi, K. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21545 · Cited by 33
Pharmacokinetics and Efficacies of Liposomal and Conventional Formulations of Tobramycin after Intratracheal Administration in Rats with PulmonaryBurkholderia cepaciaInfection
Marier, J., Lavigne, J. R., & Ducharme, M. P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3776-3781.2002 · Cited by 33
Inhaled Antimicrobial Therapy: From Cystic Fibrosis to the Flu
O’Riordan, T. G. (2000) · Respiratory Care · doi:10.1177/002013240004500707 · Cited by 30
Murine airway histology and intracellular uptake of inhaled amorphous itraconazole
Vaughn, J. M., Wiederhold, N. P., McConville, J. T., Coalson, J. J., Talbert, R. L., Burgess, D. S., Johnston, K. P., Williams, R. O., & Peters, J. I. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.02.014 · Cited by 30
Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus.
de Galan, B. E., Şimşek, S., Tack, C. J., & Heine, R. J. (2006) · PubMed · Cited by 28
Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model
Petersen, E. A., Grayson, J. B., Hersh, E. M., Dorr, R. T., Chiang, S.-M., Oka, M., & Proffitt, R. T. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.5.819 · Cited by 26
INHALED PENICILLIN IN BRONCHIAL INFECTIONS
Southwell, N. (1946) · The Lancet · doi:10.1016/s0140-6736(46)91998-8 · Cited by 25
Inhaled Amphotericin B for Prophylaxis Against Invasive Aspergillus Infections
Mohammad, R. A., & Klein, K. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g477 · Cited by 25
Toxicological evaluation of lactose and chitosan delivered by inhalation
Valle, M. J. D. J., Dinis‐Oliveira, R. J., Carvalho, F. D., Bastos, M. D. L., & Navarro, A. S. (2008) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856208783721038 · Cited by 22
Ribavirin small-particle-aerosol treatment of influenza B virus infection
Bernstein, D. I., Reuman, P. D., Sherwood, J. R., Young, E. C., & Schiff, G. M. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.5.761 · Cited by 22
Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Andrade, F., Videira, M., Ferreira, D., & Sarmento, B. F. C. C. (2011) · Drug Delivery Letters · doi:10.2174/2210303111101020171 · Cited by 22
Self-citation
In vitrocharacterization of nebulizer delivery of liposomal amphotericin B aerosols
Alexander, B. D., Winkler, T. P., Shi, S., Ashley, E. S. D., & Hickey, A. J. (2011) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2011.591803 · Cited by 19
Inhalation by design: Dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD
Jones, L. H., Baldock, H., Bunnage, M. E., Burrows, J. L., Clarke, N., Coghlan, M., Entwistle, D. A., Fairman, D., Feeder, N., Fulton, C. K., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.132 · Cited by 18
PENICILLIN INHALATION IN PULMONARY DISEASE
Humphrey, J., & Joules, H. (1946) · The Lancet · doi:10.1016/s0140-6736(46)91997-6 · Cited by 17
Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Andrade, F., Videira, M., Ferreira, D. C., et al. (2011) · Drug Delivery Letters · doi:10.2174/2210304x11101020171 · Cited by 16
Self-citation
Particulate and Vesicular Drug Carriers in the Management of Tuberculosis
Rastogi, R., Sultana, Y., Ali, A., & Aqil, M. (2005) · Current Drug Delivery · doi:10.2174/156720106775197448 · Cited by 15
Aerosol Penicillin in the Oxygen Tent
Knott, F. A., & Southwell, N. (1946) · Archives of Disease in Childhood · doi:10.1136/adc.21.105.16 · Cited by 10
Killer respiratory tract infections
Zumla, A. I. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328351f7d8 · Cited by 10
Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration
Crowder, T. M. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.3.579 · Cited by 3
Penicillin nebulization in bronchopulmonary disease; a preliminary report.
HURST, A. (1946) · PubMed · Cited by 2

Sorted by citations

The antimicrobial activity of nanoparticles: present situation and prospects for the future
Wang, L., Hu, C., & Shao, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121956 · Cited by 4,062
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,279
Nano-Strategies to Fight Multidrug Resistant Bacteria—“A Battle of the Titans”
Baptista, P. V., McCusker, M. P., Carvalho, A., Ferreira, D. A., Mohan, N. M., Martins, M., & Fernandes, A. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01441 · Cited by 917
Self-citation
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez‐Gascón, A., Almeida, A. J., & Véronique Préat, A. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 790

See all 246

Authors: Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B.
Affiliations: Universidade do Porto (PT)
University of Lisbon (PT)
Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
Corresponding author: Andrade, Fernanda
Sarmento, Bruno
ORCID: Andrade, Fernanda
Rafael, Diana
Videira, Mafalda
Ferreira, Domingos
Sosnik, Alejandro
Sarmento, Bruno
Venue: Advanced Drug Delivery Reviews
Publisher: Elsevier BV
Published: 2013-11
Volume: 65
Issue: 13-14
Pages: 1816-1827
ISSN: 0169-409X (ISSN-L)
DOI: 10.1016/j.addr.2013.07.020
PMC: PMC7103277
OpenAlex: W2010047058
Cited by: 245
References: 127
Citations by year: 2026: 11 · 2025: 15 · 2024: 23 · 2023: 22 · 2022: 21 · 2021: 29 · 2020: 23 · 2019: 26 · 2018: 11 · 2017: 17 · 2016: 10 · 2015: 19 · 2014: 16 · 2013: 1
FWCI: 2.38
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Advanced Drug Delivery Reviews (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Fundação para a Ciência e a Tecnologia (FCT) (SFRH/BD/73062/2010)
FCT (Portugal)/Ministry of Science, Technology and Innovation (MINCyT, Argentina)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: pulmonary drug delivery, respiratory infections, tuberculosis, HIV/AIDS, antibiotic resistance, immunocompromised patients
MeSH terms: Administration, Inhalation, Animals, Anti-Infective Agents, Chemistry, Pharmaceutical, Drug Carriers, Drug Resistance, Microbial, Equipment Design, Humans, Nebulizers and Vaporizers, Respiratory Tract Infections, Nanotechnology, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks